High levels of STAT1 evaluated by immunohistochemistry is associated with longer overall survival and progression-free survival of patients with high-grade serous ovarian cancer (HGSOC) (Table 1; Koti et al., 2015; Au et al., 2016; Josahkian et al., 2018). This evidence concerns the gene STAT1 and ovarian serous adenocarcinoma.